DE602005008555D1 - 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol-derivative mit cb1-antagonistischer aktivität - Google Patents

1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol-derivative mit cb1-antagonistischer aktivität

Info

Publication number
DE602005008555D1
DE602005008555D1 DE602005008555T DE602005008555T DE602005008555D1 DE 602005008555 D1 DE602005008555 D1 DE 602005008555D1 DE 602005008555 T DE602005008555 T DE 602005008555T DE 602005008555 T DE602005008555 T DE 602005008555T DE 602005008555 D1 DE602005008555 D1 DE 602005008555D1
Authority
DE
Germany
Prior art keywords
trisubstituted
dihydro
antagonistic activity
pyrazole derivative
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005008555T
Other languages
English (en)
Inventor
Josephus H M Lange
Cornelis G Kruse
Stuivenberg Herman H Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of DE602005008555D1 publication Critical patent/DE602005008555D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
DE602005008555T 2004-01-30 2005-01-27 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol-derivative mit cb1-antagonistischer aktivität Active DE602005008555D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53998304P 2004-01-30 2004-01-30
EP04100338 2004-01-30
PCT/EP2005/050339 WO2005074920A1 (en) 2004-01-30 2005-01-27 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity

Publications (1)

Publication Number Publication Date
DE602005008555D1 true DE602005008555D1 (de) 2008-09-11

Family

ID=34839806

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005008555T Active DE602005008555D1 (de) 2004-01-30 2005-01-27 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol-derivative mit cb1-antagonistischer aktivität

Country Status (21)

Country Link
EP (1) EP1713475B1 (de)
JP (1) JP4693787B2 (de)
KR (1) KR20060131861A (de)
CN (1) CN100563651C (de)
AT (1) ATE402697T1 (de)
AU (1) AU2005210163B2 (de)
BR (1) BRPI0507005A (de)
CA (1) CA2552940A1 (de)
DE (1) DE602005008555D1 (de)
DK (1) DK1713475T3 (de)
ES (1) ES2311972T3 (de)
HK (1) HK1099688A1 (de)
HR (1) HRP20080549T3 (de)
IL (1) IL176547A (de)
MX (1) MXPA06008593A (de)
NO (1) NO20063866L (de)
PL (1) PL1713475T3 (de)
PT (1) PT1713475E (de)
RU (1) RU2360904C2 (de)
SI (1) SI1713475T1 (de)
WO (1) WO2005074920A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1749820A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salze von substituierten Pyrazolin Derivaten, ihre Herstellung und Anwendung als Arzneimittel
US7829581B2 (en) 2005-07-15 2010-11-09 Laboratorios Del Dr. Esteve, S.A. Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
ES2330992B1 (es) * 2005-07-15 2010-07-06 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina heterociclilsustituidos, su preparacion y uso como medicamentos.
EP1743642A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Verwendung substituierter Pyrazolinverbindungen und ihrer Derivate zur Behandlung von Cannabinoidsystem-assoziierten Erkrankungen.
ES2337005B1 (es) * 2005-07-15 2011-01-10 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos.
EP1849784A1 (de) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indolin-substituierte Pyrazolinderivate, ihre Herstellung und Anwendung als Arzneimittel
EP1743890A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
WO2007009705A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. (rac)-n-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydr0-1h-pyrazole-3-carboxamide hydrates
EP1745783A1 (de) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazolinverbindungen, ihre Synthese und ihre Verwendung als Medikamente
ES2327379B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
ES2348374B1 (es) * 2005-07-15 2011-08-02 Laboratorios Del Dr Esteve, S.A. Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos.
EP1743888A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Carbonyl-substituierte Pyrazolin-Verbindungen zur Verwendung als CB1-Rezeptor Modulatoren
ES2326461B1 (es) * 2005-07-15 2010-04-19 Laboratorios Del Dr. Esteve, S.A. Polimorfo de n-priperidinil-5-(4-clorofenil)-1-(2,4-dicloforenil)-4,5-dihidro-1h-pirazol-3-carboxamida y su uso como modulador de receptores de cannabinoides.
WO2007009698A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Combination of pyrazoline type cannabinoid receptor antagonist and statin
EP1849776A1 (de) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepan- oder Azocan-substituierte Pyrazolinderivate, deren Herstellung und Anwendung als Arzneimittel
EP1749819A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. (rac)-N-piperidinyl-5-(4-chlorphenyl)-1(2,4-dichlorphenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid Hydraten
WO2007009682A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Oral pharmaceutical formulations comprising substituted pyrazoline compounds
EP1757588A1 (de) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Polymorph des N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamids und seine Verwendung als Cannabinoid-Rezeptor-Modulator
EP1743892A1 (de) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
EP1910302A1 (de) * 2005-07-15 2008-04-16 Laboratorios del Dr. Esteve S.A. Carbonylsubstituierte pyrazolinverbindungen, ihre herstellung und ihre verwendung als modulatoren des cb1-rezeptors
EP1745781A1 (de) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Kombination von Cannabinoid Rezeptor Antagonist des Pyrazolin-Typs und Statin
WO2007017124A1 (en) * 2005-07-29 2007-02-15 Laboratorios Del Dr. Esteve, S.A. Amorphous phase of a substituted pyrazoline, its preparation and use as medicament
EP1757589A1 (de) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Amorphe-Phase von einem substituierten Pyrazolin, deren Herstellung und Verwendung als Medikament
EP1911747A1 (de) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamid-substituierte Pyrazolin-derivate, deren Herstellung sowie deren Verwendung als CB1 Modulatoren
EP1946778A1 (de) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Wirkstoffzusammensetzung für Diabetesbehandlung
EP1946777A1 (de) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazolinderivate zur Vermeidung von Gewichtszunahme
EP1944295A1 (de) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Nicht racemische Verbindungen von (R)-N-piperidinyl-5-(4-chlorophenyl)1-1(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid und (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid
ES2328653B1 (es) * 2007-01-15 2010-05-28 Laboratorios Del Dr. Esteve S.A. Combinacion de sustancias activas para el tratamiento de la diabetes.
ES2330071B1 (es) * 2007-01-15 2010-07-05 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas.
EP1946779A1 (de) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Zusammensetzung enthaltend substituierte Pyrazoline und gegen Dyslipämie wirksame Mittel
EP1947089A1 (de) * 2007-01-18 2008-07-23 Laboratorios del Dr. Esteve S.A. A-Polymorph eines substituierten Pyrazolins, seine Herstellung und Verwendung als Medikament
US8410135B2 (en) 2007-06-15 2013-04-02 Solvay Pharmaceuticals B.V. 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
EA201070019A1 (ru) * 2007-06-15 2010-06-30 Солвей Фармасьютикалс Б.В. 4,5-дигидро-(1н)-пиразольные производные как модуляторы каннабиноидных св-рецепторов
WO2009037244A2 (en) 2007-09-20 2009-03-26 Solvay Pharmaceuticals B.V. 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists
EP2042175A1 (de) * 2007-09-21 2009-04-01 Laboratorios del Dr. Esteve S.A. Dosierungsschemata von CB1-Rezeptor-Liganden für die Behandlung von Fettleibigkeit
TW200948798A (en) * 2008-04-23 2009-12-01 Solvay Pharm Bv (5R)-1, 5-diaryl-4, 5-dihydro-1H-pyrazole-3-carboxamidine derivatives having CB1-antagonistic activity
CA2889697C (en) 2012-11-13 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
WO2014208939A1 (en) * 2013-06-28 2014-12-31 Hanmi Pharm. Co., Ltd. 1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives as cannabinoid cb1 receptor antagonist, method for preparing same, and pharmaceutical composition comprising same
CA2948349C (en) * 2014-05-09 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06500333A (ja) * 1990-01-09 1994-01-13 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺節足動物性のピラゾリン類、ピラゾリジン類およびヒドラジン類
WO1993018038A1 (en) * 1992-03-02 1993-09-16 E.I. Du Pont De Nemours And Company Arthropodicidal amides
RU2245878C2 (ru) * 2000-03-23 2005-02-10 Солвей Фармасьютикалс Б.В. Производные 4,5-дигидро-1н-пиразола, обладающие cb1-антагонистической активностью
PL363751A1 (en) * 2001-03-22 2004-11-29 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
RU2299199C2 (ru) * 2001-09-21 2007-05-20 Солвей Фармасьютикалс Б.В. Новые производные 4,5-дигидро-1h-пиразола, имеющие cb1-антагонистическую активность
CN1529595A (zh) * 2001-09-21 2004-09-15 ������ҩ�����޹�˾ 具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物

Also Published As

Publication number Publication date
BRPI0507005A (pt) 2007-06-05
CN100563651C (zh) 2009-12-02
PT1713475E (pt) 2008-11-10
IL176547A0 (en) 2006-10-31
MXPA06008593A (es) 2006-08-28
RU2006131132A (ru) 2008-03-10
HK1099688A1 (en) 2007-08-24
KR20060131861A (ko) 2006-12-20
NO20063866L (no) 2006-10-27
WO2005074920A1 (en) 2005-08-18
IL176547A (en) 2010-06-30
EP1713475A1 (de) 2006-10-25
EP1713475B1 (de) 2008-07-30
HRP20080549T3 (en) 2008-11-30
DK1713475T3 (da) 2008-12-01
RU2360904C2 (ru) 2009-07-10
PL1713475T3 (pl) 2009-03-31
AU2005210163A1 (en) 2005-08-18
AU2005210163B2 (en) 2010-05-13
ATE402697T1 (de) 2008-08-15
JP2007519686A (ja) 2007-07-19
CN1913885A (zh) 2007-02-14
SI1713475T1 (sl) 2008-12-31
JP4693787B2 (ja) 2011-06-01
ES2311972T3 (es) 2009-02-16
CA2552940A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
ATE402697T1 (de) 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität
DE602005007350D1 (de) Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
MXPA06013534A (es) Compuesto de cinamida.
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
ATE553095T1 (de) Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
GEP20125637B (en) Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
CY1117851T1 (el) Παραγωγα φαινυλ-πυρρολ-αμινογουανιδινης
DE502005008351D1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
EA200870074A1 (ru) Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
TNSN07006A1 (en) Novel heterocyclic compounds
NO20052197L (no) Fremgangsmate for fremstilling av pyrazol
WO2009037244A3 (en) 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists
MY151082A (en) Pesticidal n-phenylpyrazole derivatives
MY145008A (en) 1-arylpyrazole derivatives as pesticidal agents
MX2007007554A (es) Oxiarenos sustituidos.
UA84594C2 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists
EA201070381A1 (ru) 5-арил-4,5-дигидро-(1н)-пиразолы в качестве агонистов каннабиоидного сврецептора
EA201070019A1 (ru) 4,5-дигидро-(1н)-пиразольные производные как модуляторы каннабиноидных св-рецепторов
TH73885A (th) อนุพันธ์ 4,5-ไดไฮโดร-1h-ไพราโซลที่ถูกแทนที่สามที่ที่ 1,3,5 ที่มีการออกฤทธิ์ cb1-แอนตาโกนิสติก
TH60792A (th) อนุพันธ์ 4,5-ไดไฮโดร-1h-ไพราโซลที่มี cb1-แอนแทกโกนีสทิค แอคทิวิทีอย่างมาก

Legal Events

Date Code Title Description
8364 No opposition during term of opposition